Serotonin 5-HT1 Receptor Agonists
"Serotonin 5-HT1 Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes.
| Descriptor ID |
D058825
|
| MeSH Number(s) |
D27.505.519.625.850.800.100 D27.505.696.577.850.800.100
|
| Concept/Terms |
Serotonin 5-HT1 Receptor Agonists- Serotonin 5-HT1 Receptor Agonists
- Serotonin 5 HT1 Receptor Agonists
- 5-HT1 Agonist
- 5 HT1 Agonist
- Agonist, 5-HT1
- 5-HT1 Agonists
- 5 HT1 Agonists
- Agonists, 5-HT1
Serotonin 5-HT1B-D Agonists- Serotonin 5-HT1B-D Agonists
- 5-HT1B-D Agonists, Serotonin
- Agonists, Serotonin 5-HT1B-D
- Serotonin 5 HT1B D Agonists
- 5-HT1B-D Agonist
- 5 HT1B D Agonist
- Agonist, 5-HT1B-D
|
Below are MeSH descriptors whose meaning is more general than "Serotonin 5-HT1 Receptor Agonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin 5-HT1 Receptor Agonists".
This graph shows the total number of publications written about "Serotonin 5-HT1 Receptor Agonists" by people in this website by year, and whether "Serotonin 5-HT1 Receptor Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2012 | 3 | 0 | 3 |
| 2013 | 2 | 2 | 4 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 2 | 1 | 3 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serotonin 5-HT1 Receptor Agonists" by people in Profiles.
-
Lipton RB, Singh RBH, Revicki DA, Zhao S, Shewale AR, Lateiner JE, Dodick DW. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. J Headache Pain. 2022 Apr 25; 23(1):50.
-
Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis. Headache. 2021 Mar; 61(3):422-429.
-
Kawata AK, Shah N, Poon JL, Shaffer S, Sapra S, Wilcox TK, Shah S, Tepper SJ, Dodick DW, Lipton RB. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study. Headache. 2021 Mar; 61(3):438-454.
-
Schwedt TJ, Hentz JG, Sahai-Srivastava S, Spare NM, Martin VT, Treppendahl C, Digre K, Bennett NL, Birlea M, Watson D, Murinova N, Robert T, Dodick DW. Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial. Headache. 2021 02; 61(2):351-362.
-
Marcus SC, Shewale AR, Silberstein SD, Lipton RB, Young WB, Viswanathan HN, Doshi JA. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Cephalalgia. 2020 06; 40(7):639-649.
-
Tepper SJ, Dodick DW, Schmidt PC, Kellerman DJ. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches. Headache. 2019 04; 59(4):509-517.
-
Nation KM, Dodick DW, Navratilova E, Porreca F. Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache. Cephalalgia. 2019 04; 39(5):617-625.
-
Dodick DW, Tepper SJ, Friedman DI, Gelfand AA, Kellerman DJ, Schmidt PC. Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial. Headache. 2018 Jul; 58(7):986-992.
-
Silberstein SD. A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine. Expert Opin Drug Saf. 2018 Jan; 17(1):89-97.
-
Spierings EL, Brandes JL, Kudrow DB, Weintraub J, Schmidt PC, Kellerman DJ, Tepper SJ. Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine. Cephalalgia. 2018 02; 38(2):215-224.